www.businessgiftdepot.com

Target.com toys coupons redcard furniture baby registry careers coupon code employment review company background distributors credit blueprints complaints manual download pdf craigslist datasheet financial machine auto promo code promotion code coupons code accessories bankruptcy review scam scams promo code promotion code coupons code accessories forums blog pictures maps where affiliates address phone free shipping market markt advisors capital saves sales safe secure local address local map shop classifieds outlets industries reviews...

Target target. Com toys coupons redcard furniture baby registry careers coupon code health inc. All rights reserved target locations coupons catalogue baby registry store locator furniture pharmacy jobs center. Inc. Magazine 500 and grow rich definition lounge wiki meaning list of america's fastest-growing private companies clothing. Target biostatistics jobs tutorial salary for dummies journal introduction internships career course ucla health inc. All rights management styles concepts skills recruiters consulting games information system science by objectives jobs reserved. Planning a wedding center baby shower on budget road trip party bridal jobs checklist. Target device manager cannot start code 10 xp drivers anywhere empty vista health inc. All rights devicescape easy wifi iphone for at\x26t slacker connect ipod touch download s60 blackberry reserved. Device. Com sci fi dos. Target e*crf is devicenet cable tutorial protocol wiring connectors terminating resistor error codes troubleshooting network training a web-based, proprietary, data and project management system designed for ease of use and high throughput. Target e*crf has been used specialized bikes bikes. Com loan servicing rockhopper allez hardrock roubaix langster sirrus exclusively by target health inc. Specialized. Com bikes 2009 since 1999. It is 100% accepted by sites and has been used as toxicology and applied pharmacology jobs screen report tests letters journal definition forum screening the source crf. As a analytical chemistry skills essay thinking biochemistry engine paper geometry cubism full service cro representing over 20 companies at the fda, we understand what it takes to run a trial. Target health developed this software to streamline the process and optimize results. Target health inc. All rights reserved. . 261 madison avenue new york, ny 10016 tel. 212. 681. 2100. Feedback page please tell us what you think about our web site, company, products, or services. If you provide us with your contact information, we will be able to reach you in case we have any questions. . Target health inc. All rights reserved. . Target health inc. All rights reserved. . Target health inc. , a full-service e*cro, is committed, through creative collaboration, to serve the pharmaceutical community with knowledge, experience, technology and connectivity. Our pledge is to optimize the life cycle of drugs, biologics and devices with expertise, leadership, innovation and teamwork. We provide superior, consistent performance with a cutting edge, diverse team with the highest standards of ethical conduct and integrity. Target health inc. Is a privately held, new york city based full service e*cro with staff dedicated to all aspects of regulatory affairs, clinical research, biostatistics, data management, internet-based clinical trials (edc, electronic data capture), software development, strategic planning and drug and device development. Target health inc. Also has a group of specialized advisors in the areas of toxicology, analytical methods validation, product and process development, quality assurance and manufacturing. Over the past 5 years, target health inc. Performed data management and biostatistics for 3 approved ndas and one approved pma. Two of the approved ndas and the pma used target e*crf. Target health proprietary internet-based clinical trial software for electronic data capture, data management and project management. In 2007, 1 nda, 1 bla and 1 pma will be submitted which used target e*crf target health inc. Submits approximately 3 original inds per year, 3 4 510(k)s and currently represents 17 companies at fda and 2 companies at health canada. Target health inc. Clients include fortune 100 companies as well as many smaller companies. . 261 madison avenue new york, ny 10016 tel. 212. 681. 2100. Target health inc. All rights reserved. . This is a video of a lecture from new york biotechnology association by target health own joe lombardino, formerly from pfizer. The video can be downloaded to your computer for viewing in better quality by clicking here. Click on the image to view the video via our blog. . This is a video of a lecture from new york biotechnology association by target health own al alberts, formerly of merck. This video can be downloaded to your computer for viewing in better quality by clicking here. Click on the image to view the video via our blog. . This is a video of a lecture from new york biotechnology association by dr. Ron nardi, formerly of ferring pharmaceutical. He covers his experiences with target e*crf. Click on the image to view the video via our blog. . This is a video of a lecture from new york biotechnology association by dr. Ben levinson, formerly of infacare. He covers his experiences with target e*crf. Click on the image to view the video via our blog. . Target health inc. All rights reserved. . Target e*crf is a web-based, proprietary, data and project management system designed for ease of use and high throughput. Target e*crf has been used exclusively by target health inc. Since 1999. It is 100% accepted by sites and has been used as the source crf. As a full service cro representing over 20 companies at the fda, we understand what it takes to run a trial. Target health developed this software to streamline the process and optimize results. Target health inc. All rights reserved. . Target health inc. All rights reserved. . Target health inc. , is a full-service e*cro committed to improving the way companies run clinical trials. We have successfully used target e*crf in over 100 clinical trails. We leverage our industry knowledge, experience, technology and connectivity to streamline how companies run studies. With superior, consistent performance and a diverse team of experts, we work to the highest standards of ethical conduct and integrity. As noted by a recent client, it took a week from lplv to locked database. We could not have submitted our data and gotten approval so fast if it was not for target e*crf and your team& ,s expertise. . Target health inc. All rights reserved. . Padt is the first of its kind in the pharmaceutical industry in terms of depth, scope and experience. The team consists of experts in the areas of. Padt provides integrated, impartial and expert evaluations of all phases of a pharmaceutical development program. With the client, padt identifies opportunities for expedited development, cost and time-savings, as well as potential pitfalls. Padt can supplement in-house expertise as well as provide turn-key services. . Target health inc. All rights reserved. . Target health unveils target e*crf version 1. 7 new york--(business wire)--target health inc. , an industry-leading ecro, announced the release of version 1. 7 of target e*crf , its innovative eclinical trial software solution. This enhanced version of the more. . Target health inc. All rights reserved. . Target health inc. All rights reserved. . Paper vs. Web, a tale of three trials(applied clinical trials, august 2001). Target health inc. All rights reserved. . Target health inc. Has a highly productive medical writing group and has published manuscripts, prepared ich study reports, submitted many ind and ide and successfully completed three nda on behalf of our clients. Target health also co-authors articles and abstracts and delivers lectures throughout the year. This publications page at targethealth is another example of the company commitment to excellence. . Target health inc. All rights reserved. . Ms. Joyce hays is ceo and founder of target health inc. , a new york city based cro with expertise in regulatory affairs, including fda interactions and all submissions, strategic planning, clinical research management, biostatistics and data management, medical writing, good manufacturing practices (gmp) and other support services to the pharmaceutical industry. Ms. Hays& , responsibilities include corporate strategic planning, financial management, marketing and human resources. Previous executive experience includes co-founder and cfo of marsat development corporation (consumer products) and cfo of dobex international (gas and oil research). Ms. Hays founded the institute for interdisciplinary communication, a scientific think tank which received funding from the national science foundation. Ms. Hays earned b. S. And m. S. Degrees from columbia university in new york city. . Dr. Jules t. Mitchel is president of target health inc. , a new york city based cro with expertise in regulatory affairs, including fda interactions and all submissions, strategic planning, clinical research management, biostatistics and data management, medical writing, good manufacturing practices (gmp) and other support services to the pharmaceutical industry. Dr. Mitchel has broad base pharmaceutical experience in drugs, biologics, devices and diagnostics including three nda submission, many fda meetings and ind ide submissions, study reports, manuscripts and strategic planning. Areas of expertise include but are not limited to, women& ,s health, dermatology, antimicrobials, pharmacokinetics, rheumatology, ophthalmology, natural products, oral care, oncology and regulatory affairs. Dr. Mitchel has held industry positions at american home products, pfizer laboratories and pfizer consumer health care and academic positions at new york medical college, cornell university school of medicine and nyu school of medicine. . Target health inc. All rights reserved. . Target encoder is a secure, user friendly, web-based coding tool, to code crf terms to meddra and whodrug. Once crf terms are inputted into the system, each crf term is searched in the designated meddra or whodrug database. The system automatically codes perfect matches. If multiple matches are found, the system gives a list of possible matches. The user can select a match from the list. The manually entered term is then added to the user-defined dictionary. If no matches are found, the coder manually refines the term to match it with an appropriate term. Once this match is made, it is placed into the user-defined dictionary. All manual coding can be reversed and a list of automatically and manually coded terms are presented as a report. A glossary is also provided for all uniquely coded terms. Once crf terms are inputted into the system, each crf term is searched in the meddra who-drug databases. If a single match is found, the system accepts it. If multiple matches are found, the system gives a list of possible matches. The user can select a match from the list. The manually entered term is then added to the udd. If no matches are found, the coder manually matches the term to the appropriate lower level term (llt) through either a keyword search or a drill-down procedure starting from the soc. Once this match is made, it is placed into the udd. Prior to putting a coded term in the udd, the coder has the option to decide if this manually coded term is to be used as a default term for all subsequent coding or must be manually coded each time a new crf term with that name is identified. Once the llt is chosen, there is an associated unique preferred term (pt). Each preferred term has a unique associated high level term (hlt) and high level group term (hlgt) and a primary system organ class (psoc). The soc itself can be a unique term or can be chosen from a list of several soc terms. The system needs to be able to default to the psoc or allow the user to pick the soc, if there is more than one. Once a crf term is either automatically coded or is put into the udd, it is considered coded. The user must have the option to override a automatic or manually coded term when patient specific information indicates that a different meddra term should be used. When this is done, the term is considered coded and should not change during a subsequent coding procedure. The following reports are generated by the system. A listing of just unique terms (verbatim, llt, pt, and soc in an excel spreadsheet). This listing does not require validation and will be transmitted as an excel spreadsheet. . Target health inc. All rights reserved. . 261 madison avenue new york, ny 10016 tel. 212. 681. 2100. Feedback page please tell us what you think about our web site, company, products, or services. If you provide us with your contact information, we will be able to reach you in case we have any questions. . Target health inc. All rights reserved. . Target document is a secure, user friendly, web-based document distribution and management system which enables users, depending on their roles and responsibilities to post, share, electronically sign, search, and archive any electronic document, all within a web browser and without installing any software. Access to documents can also be timed to be viewed and or expired, and there is a communication tool which allows for discussions about specific documents. Target document minimizes the use of email and is ideal for companies wanting their own system to communicate with vendors, cros, study sites, cras, etc. It is also ideal for cros needing to deal with many sponsors. Target document can also be used in any industry and is multi-functional. Target health inc. All rights reserved. . Target document is a secure, user friendly, web-based document distribution and management system which enables users, depending on their roles and responsibilities to post, share, electronically sign, search, and archive any electronic document, all within a web browser and without installing any software. Access to documents can also be timed to be viewed and or expired, and there is a communication tool which allows for discussions about specific documents. Target document minimizes the use of email and is ideal for companies wanting their own system to communicate with vendors, cros, study sites, cras, etc. It is also ideal for cros needing to deal with many sponsors. Target document can also be used in any industry and is multi-functional. Target health inc. All rights reserved. . Target encoder is a secure, user friendly, web-based coding tool, to code crf terms to meddra and whodrug. Once crf terms are inputted into the system, each crf term is searched in the designated meddra or whodrug database. The system automatically codes perfect matches. If multiple matches are found, the system gives a list of possible matches. The user can select a match from the list. The manually entered term is then added to the user-defined dictionary. If no matches are found, the coder manually refines the term to match it with an appropriate term. Once this match is made, it is placed into the user-defined dictionary. All manual coding can be reversed and a list of automatically and manually coded terms are presented as a report. A glossary is also provided for all uniquely coded terms. Once crf terms are inputted into the system, each crf term is searched in the meddra who-drug databases. If a single match is found, the system accepts it. If multiple matches are found, the system gives a list of possible matches. The user can select a match from the list. The manually entered term is then added to the udd. If no matches are found, the coder manually matches the term to the appropriate lower level term (llt) through either a keyword search or a drill-down procedure starting from the soc. Once this match is made, it is placed into the udd. Prior to putting a coded term in the udd, the coder has the option to decide if this manually coded term is to be used as a default term for all subsequent coding or must be manually coded each time a new crf term with that name is identified. Once the llt is chosen, there is an associated unique preferred term (pt). Each preferred term has a unique associated high level term (hlt) and high level group term (hlgt) and a primary system organ class (psoc). The soc itself can be a unique term or can be chosen from a list of several soc terms. The system needs to be able to default to the psoc or allow the user to pick the soc, if there is more than one. Once a crf term is either automatically coded or is put into the udd, it is considered coded. The user must have the option to override a automatic or manually coded term when patient specific information indicates that a different meddra term should be used. When this is done, the term is considered coded and should not change during a subsequent coding procedure. The following reports are generated by the system. A listing of just unique terms (verbatim, llt, pt, and soc in an excel spreadsheet). This listing does not require validation and will be transmitted as an excel spreadsheet. . Target health inc. All rights reserved. . 1. Draft protocol to ecrf completion including creation of edit checks and uat in general, we can start working once we have a reasonable draft of the protocol as long as we agree that the majority of the navigation and forms will not change. As mentioned above, putting up the forms usually takes about a week, depending on the complexity of the study. The first study we perform together almost always takes a bit longer, but a week is a good estimate to display the forms. Form generation also goes much faster if protocols are similar. Programming of online edit checks usually takes another week plus a few days for documentation. Our final testing takes about 3-4 days. As a result, we usually plan 4 weeks from start to finish but we have been know to get a program up and running in 2 weeks. If the client does uat, it could add up to a week for the process. The only reason a release takes more than 20 work days is that the sponsor makes additional changes. We try never to be on the critical path. From ferring pharmaceuticals when both parties (ferring and target health) are committed to setup a trial quickly, we have a kpi of app. 1-2 weeks. In this area, a typical time-frame is between 2-4 weeks, never exceeding 6 weeks. From regeneron pharmaceuticals approximately 4 weeks to get a study up an running. 2. Last patient last visit to database lock here are unsolicited quotes from ferring pharmaceuticals when both parties (ferring and target health) are committed to clean file a trial quickly, we have here a kpi of app. 3-5 days. In this area, a typical time-frame is between 1-2 weeks, never exceeding 3 weeks. Congratulations for the clean file! Clean files are important milestones. Especially, when they are achieved in a record time and with all documentation so well-recorded (i guess both issues are usually linked). It should be acknowledged your enormous effort. It requires dedication and know-how to establish clean file just 8 days after the lplv. I really appreciate your efforts, persistence, continued motivation and drive for excellence. As you surely know, we had database lock for our pivotal study cs21 10 days after lplv and 3 days after last data available. This extraordinary achievement was doable thanks to all involved, including you. I wanted also to thank you especially for always going the extra mile for us whenever needed. From regeneron pharmaceuticals approximately 4 - 5 weeks. Depends on the monitoring. Target health experience there is no question if the monitoring is good, database lock can occur within a week of the last monitoring visit. Our experience is 2-4 weeks. 3. Database lock to creation of tables listings figures from regeneron pharmaceuticals approximately 1 week to draft tfls. Final tfls took about 3-4 weeks (one review cycle). Target health experience we release draft tfls within 2 days of database lock. Most of the time, we have reviewed the tfls with the client with a dummy randomization code, so that are usually few changes after database lock. We usually finalize tfls within 2-5 days of database lock. The only reason it would be longer is if the client changes their mind, which does happen. 4. Database lock to draft clinical study report. From regeneron pharmaceuticals we aim for 8 weeks. It can be more like 10-12. Target health experience we usually release the draft report within 3 weeks of database lock. For additional questions or to schedule a demo, please contact jules mitchel, president 212-681-2100 julesmitchel@targethealth. Http blog. Targethealth www. Targethealth. Target health inc. All rights reserved. . Post, share, electronically sign, search, archive, etc. Any electronic document. Target health inc. All rights reserved. . Target health inc. All rights reserved. . Target ctms is a secure, user friendly, web-based clinical trial management system which enables users, depending on their roles and responsibilities to manage a clinical trial, all within a web browser and without installing any software. Target ctms reduces the need to distribute documents via email and is ideal for companies wanting their own system to manage sponsors, sites, irbs, study startup, and study progress. Together with target e*crf and target document, target ctms fulfills the trilogy of products needed to manage a clinical trial from cradle to grave. Clinical trial management involves tracking of regulatory documents and clinical trial operations. For example, all clinical trials require the same regulatory documentation (e. G. Signed form 1572, signed investigator cv s, ethics committee approval of protocols, protocol amendments and informed consent forms, annual ethics committee approval of protocols, etc. ). Regulatory documents also have project management related information such as completion date, submission date, approval date, and notes such as who& ,s in charge, activities, and etc. Tracking of documents involves knowing where a document is in terms of the project progression and taking actions at appropriate time. Clinical trial management also involves tracking of the overall status of patient enrollment and other metrics associated with a clinical trial, managing personnel scheduling, as well as tracking communications between the sponsor, cro and clinical sites. Download data sheet. Target health inc. All rights reserved. . Target health inc. All rights reserved. . Target health inc. All rights reserved. . Directed programs in the areas of atherosclerosis, diabetes and obesity. Responsible for the discovery and development of merck lovastatin and simvastatin. Also, involved in the discovery of natural products and combinatorial chemicals. . Areas of expertise include drug and device good manufacturing practices (gmps), quality assurance, quality control, environmental compliance, hazardous waste regulations, and iso 9000. Formerly at advanced polymer systems. . Dr. Cori gorman, who is a partner in the firm dna bridges, inc. , is a recognized expert in the biotechnology industry having 16 years experience in this field as a research scientist and administrator. Her experience in strategic planning includes work in genomics, functional genomics and microarray screening, vaccine development, including dna vaccines, tools for gene targeting and persistent gene expression, cancer, cell biology and neurobiology. She has an outstanding record of achievement in basic research and drug development applications in diverse areas including gene therapy, gene expression, and transfer, hormone processing, cell biology, protein transport, and the humanization and production of recombination of proteins. Two projects have resulted in marketed therapeutics and four projects have therapeutics currently in clinical trials. Dr. Gorman has worked for such industry leaders as genentech while also being experienced in all aspects of a start-up company. She has a strong publication (over 13,000 citations and 6 classic citations) and presentation record. Dr. Gorman developed the cat assay in 1980 as a postdoctoral fellow in the lmb nci. This assay was developed as a sensitive determiner of gene expression and was the industry standard for over more than fifteen years. . Brings over 10 years of experience in the area of toxicology. Holds a m. S. In toxicology from university of arizona as well as board certification (d. A. B. T. ). Specializes in the development nonclinical toxicology testing programs for new drugs. Prepares toxicology summaries for drug and medical device submissions, develops protocols, monitors toxicology programs, interacts with fda, conducts due diligence audits. . He brings 18 years of experience in the area of bioanalysis, pharmacokinetics and drug metabolism for pharmaceutical development. He held positions as director of preclinical adme at dupont merck pharmaceuticals and executive director of preclinical safety and drug disposition at cocensys and currently the president and ceo of microconstants, a full service bioanalytical company specialized in hplc ms analysis. . Spent 41 years at pfizer central research where he discovered feldene, the first once-a-day treatment of arthritis. Formed and headed the department of development planning which established matrix teams and project management techniques to the drug development process. Most recently, was senior director of operations planning at pfizer central research. Has published 64 scientific papers including 2 books and holds 56 patents. . Dr. Andrew r. Mccullough is assistant professor of clinical urology and director of male sexual health and fertility in the urology department at the new york university medical center. In 1974 he completed his undergraduate work in natural sciences at the johns hopkins university in baltimore and in 1978 his medical school training at the university of maryland school of medicine in baltimore. After his surgical internship at the university of florida shands teaching hospital, he returned to the johns hopkins university for his urology training. In 1981 he completed a one year fellowship in uro-oncology and in 1983 completed his urology residency, under the tutelage of patrick c. Walsh at brady urological institute of the johns hopkins university hospital. He joined the clinical faculty at johns hopkins as clinical instructor in 1983. In 1984 he moved to new haven and joined the clinical urology faculty at the yale school of medicine as clinical instructor. In addition to his teaching responsibilities to the medical students and urology residents at yale university he also engaged in a busy practice of general urology in new haven. In 1994 he joined dr. Herbert lepor, dr. Ellen shapiro and dr. Christopher dixon to help restructure the urology department and residency program at new york university medical center. Since 1994 he has subspecialized in malesexual health and fertility tapping into 10 years of general urologic practice. He holds hospital appointments at the nyu-mount sinai medical center and the manhattan veterans admistration hospital. He has studied with dr. Tom lue in san francisco and collaborating with his wife, dr. Joanna fine, a psychiatrist and clinical instructor in the department of psychiatry at nyu, he seeks to provide a comprehensive approach at the diagnosis and treatment of male sexual dysfunction. He has lectured and presented papers nationally and internationally both in the areas of male sexual health and fertility and frequently donates his time to lecture at local resolve and american infertility institute support group meetings to educate infertile couples. He has been principle investigator in numerous clinical trials in erectile dysfunction including the pivotal sildenafil trials. Currently he is conducting ed trials with bayer, tap, liliy-icos and pfizer as well as investigator initiated collaborative projects with the departments of psychiatry and reproductive endocrinology. Dr. Mccullough is board certified in adult and pediatric urology and has served as a high level advisor and expert to many companies including pfizer, bayer, bristol meyers squibb, vivus, schering-plough, smith kline beecham, and tap. He is a fellow of the american college of surgeons, member of the society for male reproduction, american society of andrology, american urological association, society of sex therapy and research and the society for the study of male reproduction. Areas of active research include the study of post radical prostatectomy erectile dysfunction, female sexual dysfunction, the effect of sperm cryo-preservation of post ivf-icsi miscarriage rates, and the impact of aging on human seminal parameters. . Analytical methods development including validations, stability studies and process product trouble shooting. Formerly at ethicon, inc. . Otto mills joined the university of pennsylvania& ,s graduate group on molecular biology in 1965 and the department of dermatology, school of medicine in 1967. His first appointment at the university of medicine and dentistry of new jersey, robert wood johnson medical school was in 1984, where he is a member of the division of dermatology. He has authored or co-authored over two hundred publications and lectured by invitation at universities and medical meetings in the united states, europe and asia. Dr. Mills has served as chair of dermatologic and allergic diseases, american society of clinical pharmacology and therapeutics, and he is a fellow of the american college of clinical pharmacology. His other memberships include sigma xi (university of pennsylvania), the american federation for medical research, the society for investigative dermatology and the american academy of dermatology. Among the awards he has received for original research are those from the american academy of dermatology (1970, 1981, 1985), the college of physicians of philadelphia (1971), the medical society of new jersey (1975), the american medical association (1975), and the southern medical association (1971). . Specializes in marketing, market research, product launches, medical education. Strong scientific and marketing background allows david to work with both traditional and biotech products. . Holds a ph. D. In toxicology from utah state university. Specializes in fda interactions and strategies, preparations of ind, ide, pma and nda toxicology sections. Manages entire nonclinical toxicology programs including program design, protocol preparation, placement and execution of nonclinical studies, preparation of study reports and their inclusion into regulatory submissions. Formerly vice president of the life sciences at hazelton laboratories. . Howard rubin, m. A. - product and process development. Research and development executive with more than thirty years of consumer and professional pharmaceutical and cosmetic product development experience. Formerly at johnson johnson, block drug, warner-lambert, hoffman-laroche bristol-myers. . After completing a ph. D. In pharmaceutical chemistry from the university of kansas, dr. Wolfe was awarded a post doctoral fellowship at the national institutes of health clinical center pharmaceutical development section where she was involved in developing nih-generated compounds for use in clinical trials. Following her stay at nih, dr. Wolfe was appointed assistant professor at the university of tennessee, where she expanded her expertise in pharmaceutical analysis, pharmaceutical preformulation and formulation. Following tennessee, she founded wolfe laboratories inc. (www. Wolfelabs), a contract research organization providing research and development services to the pharmaceutical and biotechnology industries. . Target health inc. All rights reserved. . Clinical pharmacology and therapeutics, february 2005. Pediatric web trial. . Target health inc. All rights reserved. . Target health inc. All rights reserved. . Target health inc. Is a founding member of asian clinical trial network (actn). The actn is a consortium of cros and clinical study sites, committed to the implementation and execution of gcp clinical trials in asia. . Target health inc. All rights reserved. . In the development of the software. Ferring has two ndas approved which used target health current edc software, target e*crf. . All our global studies are now solely edc based - we would never go back to paper. Our new benchmark for locking a database, once all the information is available is one day. Senior vice president global clinical research development. Hi, i just want to thank you. I know you have been working so hard to meet our ever-changing, highly-demanding needs, and i just want to let you know how much we appreciate it. It is a pleasure to be working with you. With kind regards imogene grimes, ph. D. , vice president, biostatistics and data management, regeneron pharmaceuticals. . Using target health& ,s internet-based clinical trial system, target e*crf, we are able to monitor device safety in real-time in a high-risk neonates undergoing cardiac surgery. Its nice to know the status of patient enrollment and data entry without having to contact the clinical study sites directly. Eli pines, ph. D. Vice president and chief scientific officer, synthemed, inc. . With electronic data capture by the target e*crf system, we have been able to view site activities (data entry, queries, audits) in real time and save a great deal of time and money through our ability to quickly lock a data base and perform interim analyses when necessary. With target document, we have been able to seamlessly manage documents, in a cost-effective way, for a worldwide trial in pediatrics, without the need of multiple paper copying, email and overnight express carriers. Benjamin levinson, md, vice president, drug development, wellspring pharmaceutical corporation. . My sincere thanks for a job well done. These timelines, i can tell you would be the envy of 99% of the industry. What a difference hard work and planning makes. Patrick oconnor, senior vice president, global clinical research development, ferring pharmaceuticals, copenhagen. . Congratulations for the clean file! Clean files are important milestones. Especially, when they are achieved in a record time and with all documentation so well-recorded (i guess both issues are usually linked). It should be acknowledged your enormous effort. It requires dedication and know-how to establish clean file just 8 days after the lplv. I really appreciate your efforts, persistence, continued motivation and drive for excellence. Jca, md executive, director, obstetrics gynecology, clinical research development, ferring pharmaceuticals, copenhagen. . With target e*crf, we have been able to keep completely informed of the study status any where in the us and were able to do a key interim analysis within 2 days of the final patient measurement. Sam lynch, dmd, president, biomimetic pharmaceuticals, inc. . With target e*crf, we were able to utilize a web-based central randomization schema, which allowed us to stratify and randomize patients across the us, western europe, eastern europe and india. We were also able to view data in real time and anywhere on the globe. This was tested and verified by myself. Marian gorecki, ph. D. , c. E. O. , mediwound ltd, israel. As you surely know, we had database lock for our pivotal study cs21 10 days after lplv and 3 days after last data available. This extraordinary achievement was doable thanks to all involved, including you. I wanted also to thank you especially for always going the extra mile for us whenever needed. Silvana cappi, ferring. I am writing this email to express my sincere thanks to you. I just went through all scenarios for the visual acuity calculations in 0702 study. No issues are identified. I sent the scenario table to you and we went over the table in 10 15 minutes. In contrast, the same table was sent to another vendor, i spent ~20 hours to go through all situations in details. I still identified over 10 problems this weekend. Thanks making my life easy!! Senior clinical data manager. . 1. Dear jules, you may already have heard about this (via ferring us), but we finally got nda approval and launched repronex on august 11th, 2003. It has been very busy. My sincere thanks for your contribution as it was vital to the approval. Rick jeysman, president, ferring canada. First of all many thanks for sending me the orphan drug designation. Well done from your side! Dr. Bernd rosenkranz, vp clinical development, jerini ag. Many thanks to the whole submission team at target health and at jerini for the successful and timely canadian cta submission, which will be an important step in getting the us (now us canadian) trial done on time. Dr. Bernd rosenkranz, vp clinical development, jerini ag. Target health inc. All rights reserved. . .

Support in counties (state):

• Garrard County, Kentucky
• Tioga County, Pennsylvania
• Sherman County, Texas
• Jackson County, Indiana
• Clarke County, Georgia
• Lake County, Illinois
• Bienville County, Louisiana
• Newton County, Indiana
• Hidalgo County, Texas
• Jefferson County, Nebraska
• Stephens County, Georgia
• Nicholas County, West Virginia
• Cowley County, Kansas
• Van Buren County, Michigan
• Maury County, Tennessee
• Wyoming County, Pennsylvania
• Cherokee County, Georgia
• Logan County, Kentucky
• Crittenden County, Kentucky
• Guadalupe County, New Mexico
• Sedgwick County, Colorado
• Houghton County, Michigan
• Kankakee County, Illinois
• Emporia City, Virginia
• Windham County, Connecticut
• Hancock County, Iowa
• Hamilton County, Iowa
• Clay County, South Dakota
• Torrance County, New Mexico
• Weakley County, Tennessee
• Ramsey County, Minnesota
• Marengo County, Alabama
• Oklahoma County, Oklahoma
• Robeson County, North Carolina
• La Salle County, Illinois
• Cayuga County, New York
• Orange County, New York
• Wallowa County, Oregon
• Wapello County, Iowa
• Scott County, Mississippi
• Madison County, Louisiana
• East Carroll County, Louisiana
• Stone County, Mississippi
• Loudon County, Tennessee
• Mono County, California
• Hot Spring County, Arkansas
• Sunflower County, Mississippi
• Orange County, California
• Curry County, New Mexico
• Bonneville County, Idaho
• Hardin County, Iowa
• Buncombe County, North Carolina
• Adams County, Washington
• Franklin County, Louisiana
• Tift County, Georgia
• Charles County, Maryland
• Pennington County, South Dakota
• Hardin County, Ohio
• Trempealeau County, Wisconsin
• Monroe County, New York
• Prince George County, Virginia
• Lincoln County, Montana
• De Soto County, Florida
• Faulkner County, Arkansas
• Freestone County, Texas
• Choctaw County, Mississippi
• Bedford County, Pennsylvania
• Peoria County, Illinois
• Union County, Louisiana
• Washington County, Indiana
• Fleming County, Kentucky
• McMullen County, Texas
• Vermillion County, Indiana
• Jasper County, Texas
• Rabun County, Georgia
• Wheeler County, Texas
• Augusta County, Virginia
• Oconee County, Georgia
• Fulton County, Illinois
• Pawnee County, Oklahoma
• Miami County, Indiana
• Cocke County, Tennessee
• Warren County, Tennessee
• Hillsdale County, Michigan
• Fremont County, Idaho
• Lyon County, Nevada
• Clearfield County, Pennsylvania
• Walla Walla County, Washington
• Dodge County, Minnesota
• Morgan County, Georgia
• Jones County, Iowa
• Broomfield County, Colorado
• St. Mary's County, Maryland
• Cecil County, Maryland
• St. Mary County, Louisiana
• Marshall County, Mississippi
• Radford City, Virginia
• Concho County, Texas
• Albany County, Wyoming
• Orange County, Florida
• Christian County, Kentucky
• Clare County, Michigan
• Routt County, Colorado
• Kenedy County, Texas
• Baker County, Oregon
• Rock County, Wisconsin
• Washington County, Oklahoma